ARID1A upregulation predicts better survival in patients with urothelial bladder carcinoma

Qifeng Cao, Chen Wang, Yu Ding, Ding Xu, Subo Qian, Haibo Shen, Jun Qi, Qifeng Cao, Chen Wang, Yu Ding, Ding Xu, Subo Qian, Haibo Shen, Jun Qi

Abstract

Objective: AT-rich interactive domain-containing protein 1A (ARID1A) is frequently mutated or deficient in various types of tumors. However, the role of ARID1A in bladder cancer remains unclear. We aimed to evaluate ARID1A expression and its biological role and correlation with prognosis in patients with urothelial bladder carcinoma (BUC).

Methods: ARID1A expression levels in BUC and normal tissues were assessed by immunohistochemistry and correlated with clinicopathological characteristics and patient outcomes. Downregulation of ARID1A was mimicked by transfection with small interfering RNA in T24 bladder cancer cells, and the effects on cell proliferation and migration were evaluated.

Results: ARID1A expression was significantly reduced in BUC tissues and was significantly associated with T stage and AJCC stage. Upregulation of ARID1A predicted a better prognosis in BUC patients. ARID1A expression and lymph node status were identified as independent prognostic factors for overall survival. Silencing of ARID1A promoted the proliferation of BUC cells.

Conclusions: ARID1A may represent a novel diagnostic and prognostic biomarker in patients with BUC.

Keywords: ARID1A; bladder cancer; migration; prognosis; proliferation; tumor suppressor.

Figures

Figure 1.
Figure 1.
ARID1A expression in bladder urothelial carcinoma (BUC) tissues and normal tissues. (a) ARID1A expression was decreased in 66 BUC tissue samples compared with 22 normal tissue samples.P-values were calculated by unpaired Student’st-tests. (b) Representative immunohistochemical staining of ARID1A in tumor and normal tissues. IHC, immunohistochemistry.
Figure 2.
Figure 2.
ARID1A expression in bladder urothelial carcinoma tissues. Representative immunohistochemistry staining of ARID1A in low-expression (upper panel) and high-expression groups (lower panel). ARID1A-positive staining was predominantly located in the nucleus.
Figure 3.
Figure 3.
Overall survival (OS) and cancer-specific survival (CSS) in patients with urothelial bladder carcinoma based on ARID1A expression. Kaplan–Meier analysis of OS (a) and CSS (b). P-values were calculated using the log-rank (Mantel–Cox) test.
Figure 4.
Figure 4.
Silencing of ARID1A enhanced the proliferation and migration of bladder cancer (BC) cells. (a) ARID1A expression was reduced in cells transfected with ARID1A siRNA. (b) Silencing of ARID1A promoted the proliferation of BC T24 cells determined by CCK-8 assay (c) and promoted the migration of T24 BC cells determined by Transwell assay. **P<0.01. NC, negative control.

References

    1. Oosterhuis JW, Schapers RF, Janssen-Heijnen MLet al. Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol 2002; 55: 900–905.
    1. Chaux A, Karram S, Miller JSet al. High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Hum Pathol 2012; 43: 115–120. DOI: 10.1016/j.humpath.2011.04.013.
    1. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374: 239–249. DOI: 10.1016/s0140-6736(09)60491-8.
    1. Botteman MF, Pashos CL, Redaelli Aet al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315–1330. DOI: 10.1007/BF03262330.
    1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471–1474. DOI: 10.1245/s10434-010-0985-4.
    1. Ayhan A, Mao TL, Seckin Tet al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 2012; 22: 1310–1315. DOI: 10.1097/IGC.0b013e31826b5dcc.
    1. Jones S, Wang TL, Shih IeMet al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228–231. DOI: 10.1126/science.1196333.
    1. Liang H, Cheung LW, Li Jet al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012; 22: 2120–2129. DOI: 10.1101/gr.137596.112.
    1. Guichard C, Amaddeo G, Imbeaud Set al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44: 694–698. DOI: 10.1038/ng.2256.
    1. Fujimoto A, Totoki Y, Abe Tet al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012; 44: 760–764. DOI: 10.1038/ng.2291.
    1. Imielinski M, Berger AH, Hammerman PSet al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107–1120. DOI: 10.1016/j.cell.2012.08.029.
    1. Mamo A, Cavallone L, Tuzmen Set al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 2012; 31: 2090–2100. DOI: 10.1038/onc.2011.386.
    1. Wang DD, Chen YB, Pan Ket al. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One 2012; 7: e40364. DOI: 10.1371/journal.pone.0040364.
    1. Huang J, Deng Q, Wang Qet al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012; 44: 1117–1121. DOI: 10.1038/ng.2391.
    1. Yan HB, Wang XF, Zhang Qet al. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription. Carcinogenesis 2014; 35: 867–876. DOI: 10.1093/carcin/bgt398.
    1. Guan B, Wang TL, Shih IeM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011; 71: 6718–6727. DOI: 10.1158/0008-5472.CAN-11-1562.
    1. Gui Y, Guo G, Huang Yet al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011; 43: 875–878. DOI: 10.1038/ng.907.
    1. Faraj SF, Chaux A, Gonzalez-Roibon Net al. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. Hum Pathol 2014; 45: 2233–2239. DOI: 10.1016/j.humpath.2014.07.003.
    1. Balbas-Martinez C, Rodriguez-Pinilla M, Casanova Aet al. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. PLoS One 2013; 8: e62483. DOI: 10.1371/journal.pone.0062483.
    1. Iyer G, Hanrahan AJ, Milowsky MIet al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221. DOI: 10.1126/science.1226344.
    1. Wang K, Kan J, Yuen STet al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011; 43: 1219–1223. DOI: 10.1038/ng.982.
    1. Romero OA, Setien F, John Set al. The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer. EMBO Mol Med 2012; 4: 603–616. DOI: 10.1002/emmm.201200236.
    1. Samartzis EP, Gutsche K, Dedes KJet al. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 2014; 5: 5295–5303. DOI: 10.18632/oncotarget.2092.
    1. Bitler BG, Aird KM, Garipov Aet al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 2015; 21: 231–238. DOI: 10.1038/nm.3799.
    1. Helming KC, Wang X, Wilson BGet al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 2014; 20: 251–254. DOI: 10.1038/nm.3480.
    1. Nagl NG, Jr., Patsialou A, Haines DSet al. The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res 2005; 65: 9236–9244. DOI: 10.1158/0008-5472.CAN-05-1225.
    1. Dykhuizen EC, Hargreaves DC, Miller ELet al. BAF complexes facilitate decatenation of DNA by topoisomerase IIalpha. Nature 2013; 497: 624–627. DOI: 10.1038/nature12146.
    1. Zang ZJ, Cutcutache I, Poon SLet al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012; 44: 570–574. DOI: 10.1038/ng.2246.
    1. Zhang X, Zhang Y, Yang Yet al. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol 2012; 36: 288–293. DOI: 10.1016/j.canep.2011.07.006.
    1. Samartzis EP, Noske A, Dedes KJet al. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci 2013; 14: 18824–18849. DOI: 10.3390/ijms140918824.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner